Here are the 10-Q quarterly reports from Provectus Biopharms (PVCT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PVCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PVCT filings page.
Provectus Biopharmaceuticals, Inc. reported a net loss of $1,273,710 for the quarter ended September 30, 2026, compared with $1,323,629 a year earlier; nine-month net loss was $3,563,375 versus $4,337,312. It reported no revenue from product sales or commercial operations. Nine-month grant revenue was $0, down from $336,108, while operating cash use was $1,575,409 versus $2,456,438.
Cash was $180,733 at September 30, 2026, and the working capital deficit was $6,730,268, compared with $251,291 and $6,329,504 at December 31, 2025. Management said its plans do not alleviate substantial doubt about the company’s ability to continue as a going concern within one year after the statements are issued; it plans to seek additional capital.
At September 30, $2,796,514 of principal and interest remained on 2025 Notes, which automatically convert into preferred stock at maturity. After quarter-end, $480,897 converted into 168,031 Series D-1 preferred shares at $2.862 per share.
Provectus Biopharmaceuticals reported a net loss of $988,716 for the quarter and $2,289,665 for the six months ended June 30, 2026, both markedly lower than the prior-year periods as operating expenses declined. Research and development spending fell sharply, mainly from reduced clinical and manufacturing activity, while general and administrative costs also decreased on lower professional fees, payroll, legal and stock-based compensation.
Cash increased to $1,156,915 from $251,291 at year-end 2025, helped by $1,695,000 of new 2025 convertible notes and $75,000 raised at majority-owned subsidiary VisiRose, but the company still had a working capital deficit of $6,338,261 and an accumulated deficit of $265,126,832. Management disclosed that these conditions raise substantial doubt about the company’s ability to continue as a going concern and stated that continued operations depend on successfully developing its RBS-based drug candidates and raising additional capital, including through its 2025 Financing convertible note program.
Provectus Biopharmaceuticals, Inc. reported a net loss of $1.3 million for the three months ended March 31, 2026, compared with $1.16 million a year earlier. Grant revenue fell from $278,628 to zero as a prior Tennessee grant was fully recognized in 2025.
Research and development expenses declined 17.2% to $333,334, and general and administrative costs decreased 6.1% to $914,569, reflecting lower clinical activity, professional fees, and stock-based compensation, partly offset by higher legal and software costs. Cash was $223,883 at March 31, 2026, with a working capital deficit of $6.78 million and an accumulated deficit of $264.1 million.
The company discloses that these conditions raise substantial doubt about its ability to continue as a going concern and states it must secure additional financing, including through its 2025 unsecured convertible notes program, equity offerings, or collaborations to fund operations and planned clinical development of its RBS-based drug candidates.
Provectus Biopharmaceuticals (PVCT) reported Q3 2025 results with continued operating losses and very limited liquidity. Net loss was $1.32 million for the quarter and $4.34 million for the nine months ended September 30, 2025. Cash was $72,479 as of September 30, 2025, and management stated these conditions raise substantial doubt about the company’s ability to continue as a going concern.
The company used $2.46 million in operating cash flow year‑to‑date and reported a working capital deficit of $6.19 million as of September 30, 2025. To fund operations, Provectus raised $1.525 million in unsecured 2025 convertible notes during the nine months, which bear 8% interest and automatically convert to Series D‑1 Preferred Stock after 12 months at $2.862 per share; each Series D‑1 share is convertible into 10 common shares.
The company also converted prior‑period notes into equity, issuing 869,415 Series D‑1 Preferred shares during the nine months. Common shares outstanding were 420,279,879 as of November 12, 2025. Operating expenses rose, led by general and administrative costs and stock‑based compensation, while grant revenue concluded by mid‑2025.